Hypoxanthine Derivatives in Experimental Infections
In vivo treatment with parenterally administered hypoxanthine derivatives, notably ST 789, was able to protect cyclophosphamide-immunosuppressed mice against experimental infections with both bacterial and fungal pathogens. However, the mechanisms accounting for these effects of hypoxanthine derivat...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1992-01-01
|
| Series: | Canadian Journal of Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/1992/181709 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | In vivo treatment with parenterally administered hypoxanthine
derivatives, notably ST 789, was able to protect cyclophosphamide-immunosuppressed mice against
experimental infections with both bacterial and fungal pathogens. However, the mechanisms accounting
for these effects of hypoxanthine derivatives remain to be fully established. In fact, only the treatment with
ST 789 resulted in a clear enhancement of the primary antibody production as well as macrophage
phagocytic activity, whereas T lymphocyte responsiveness to mitogens and both macrophage- and natural
killer-dependent cytotoxicity were not significantly affected. These data, together with the recently shown
ability of ST 789 to increase interleukin-6 production, suggest that monocyte/macrophages are likely to be the main cellular target of the immunomodulating activity of ST 789. Finally, in the presentln vivo study, hypoxanthine derivatives did not enhance the mean survival time of tumour-bearing immunosuppressed mice. |
|---|---|
| ISSN: | 1180-2332 |